Abstract
Background The US Preventive Services Task Force updated colorectal cancer (CRC) screening guidelines in 2021, recommending screening for adults aged 45-49. This study aimed to evaluate CRC screening prevalence among this newly eligible population and examine associations with healthcare provider supply and CT colonography facility availability in 2022.
Methods Using 2022 Behavioral Risk Factor Surveillance System data (n=25,592), we estimated CRC screening prevalence among adults aged 45-49. We examined associations between screening rates and state-level healthcare provider supply using 2021-2022 Area Health Resources File data. Spearman rank-order correlations assessed relationships between provider supply, CT colonography facility availability, and screening prevalence.
Results Overall CRC screening prevalence was 34.5% (95% CI: 33.4%-35.8%). Endoscopic tests were most common (74.9%), followed by stool-based tests (9.3%) and CT colonography (0.5%). Significant variations in screening modalities were observed across sociodemographic factors. Gastroenterology physician supply positively correlated with overall CRC screening prevalence (ρ=0.42, P=.002) and endoscopy screening prevalence (ρ=0.39, P=.005). CT colonography facility availability weakly correlated with CT colonography screening prevalence (ρ=0.18, P=.22).
Conclusions CRC screening rates among newly eligible adults aged 45-49 appear to be suboptimal in 2022. Disparities in screening methods across sociodemographic factors highlight potential access barriers. The association between gastroenterology physician supply and screening rates emphasizes the importance of addressing projected workforce shortages. Targeted efforts are needed to increase CRC screening uptake in this age group and ensure equitable access to screening services.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study used ONLY openly available human data that were originally located at: the Behavioral Risk Factor Surveillance System (BRFSS) 2022 dataset: https://www.cdc.gov/brfss/annual_data/annual_2022.html
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
